NEW YORK (GenomeWeb News) – Horizon Discovery said today that it has signed a commercial service agreement with GlaxoSmithKline in the area of cancer metabolomics.
Under the agreement, Cambridge, UK-based Horizon will use its X-MAN cell lines to provide GSK with services including the characterization of biomarkers, disease signatures, and therapeutic targets.
Financial terms of the agreement were not disclosed.
Horizon said that its X-MAN isogenic cell lines provide genetically defined and patient-relevant in vitro models of human cancer to help companies discover and develop targeted or personalized cancer therapeutics.